Adaptimmune Therapeutics reported TECELRA net sales of $4.0 million for the first quarter ended March 31, 2025. The company initiated full-year 2025 TECELRA sales guidance in the range of $35 million to $45 million. As of May 13, 2025, 28 Authorized Treatment Centers (ATCs) were available, 21 patients had been apheresed year-to-date, and 14 doses had been invoiced.
The company reported a net loss of $47.584 million for Q1 2025, compared to a net loss of $48.503 million for the same period in 2024. Operating expenses totaled $53.018 million in Q1 2025, down from $54.939 million in Q1 2024, reflecting the initial impact of cost reduction efforts. Cash flow from operations was a significant outflow of $66.6 million in Q1 2025, impacted by the timing of R&D tax credit receipts and redundancy payments.
As of March 31, 2025, Adaptimmune's Total Liquidity stood at $59.6 million. The company's 2024 Annual Report on Form 10-K, filed on March 24, 2025, disclosed substantial doubt about its ability to continue as a going concern, as its existing cash and marketable securities are not sufficient to fund operations for at least the next 12 months. The company continues to explore strategic options and additional funding to bridge to profitability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.